Page 5,880«..1020..5,8795,8805,8815,882..5,8905,900..»

Online pharmacy pioneer imprisoned in U.S. fraud case

Posted: Published on January 10th, 2013

A Canadian who helped create the cross-border online pharmacy industry has been sentenced to four years in a U.S. prison for his involvement in a scheme to defraud American customers. Andrew Strempler received the sentence on Wednesday, and was also ordered to pay a forfeiture of $300,000 US and a $25,000 fine, the U.S. Justice Department said in a release. A restitution hearing has been slated for Feb. 26. Strempler pleaded guilty in October to conspiracy to commit mail fraud in connection with his role as owner and president of Mediplan Health Consulting Inc., a Canadian company, which also operated under the name RxNorth.com. RxNorth was an online, mail- and telephone-order pharmacy, through which Strempler and others marketed and sold prescription drugs to U.S. residents. Strempler, who was originally from Manitoba, was one of the first entrepreneurs in the cross-border online pharmacy industry. He was arrested in Florida in June. The charges against him relate to a 2005 seizure of prescription drugs shipped by Mediplan. The U.S. Food and Drug Administration claimed that many of the drugs, which were promoted as Canadian, actually came from other countries. In a release, U.S. justice officials say Strempler obtained the medications from various … Continue reading

Posted in Pharmacy | Comments Off on Online pharmacy pioneer imprisoned in U.S. fraud case

Pharmacy Owner Says Shooting was Attempted Assassination

Posted: Published on January 10th, 2013

January 9, 2013 Updated Jan 9, 2013 at 6:20 PM PST Business continued as usual at the Almond Avenue Pharmacy in Madera. Its something owner Bryan Lee never would have imagined, Tuesday night. At around 6:30 p.m., two men in ski masks barged into his pharmacy on Almond Avenue. He says they made their way through the back door. It was not a robbery so much as it was an execution. It was an attempted assassination. They didn't make any demands. They simply came in, went over here, I mean they were basically trying to shoot us in the back of the head, explained Lee. His mother, Sophie, was shot in the leg. He said it all happened so fast. He explained, I ducked down behind the counter and he kept firing and I was afraid they were going to kill both of us. That's when Lee said he grabbed his gun and shot back. Police say Lee hit the shooter, 31-year-old Aquilla Bailey in the face, torso and leg, killing him. Police say Bailey is a gang member from Fresno. The second man, who wasn't armed, was able to get away. Police are still trying to find a motive, … Continue reading

Posted in Pharmacy | Comments Off on Pharmacy Owner Says Shooting was Attempted Assassination

PBMI's Annual Drug Benefit Conference Moves to Las Vegas, Nevada — February 18-20, 2013

Posted: Published on January 10th, 2013

PLANO, TX--(Marketwire - Jan 10, 2013) - The Pharmacy Benefit Management Institute (PBMI) is pleased to announce that it has moved the PBMI annual conference venue to Las Vegas, Nevada.The 18th Annual Drug Benefit Conference will be held at the MGM Grand Hotel February 18-20, 2013.Conference attendees will learn about best practices and strategies to help manage the traditional and specialty drug benefit. This year the conference features an opening keynote from an award-winning author, a Specialty 101 Pre-Conference Workshop, and 21 presentations (includes 15 breakout sessions) presented by industry experts. "Recognizing that specialty drug benefits raise a new different set of challenges and complexities, at last year's conference, we introduced a full three-day Specialty program option that was very well received by attendees.This year we have implemented two Specialty program tracks in addition to a Traditional Pharmacy program for attendees to follow," said Brenda Motheral, Executive Director, PBMI."We have expanded our agenda to also include a Specialty 101 Pre-Conference Workshop that will offer the opportunity for attendees to master the fundamentals of specialty drug management." Conference Highlights Include: For Conference details view the Conference Program.To learn more about the conference, contact Linda DeChant, Sales Director at ldechant@pbmi.com or visit … Continue reading

Posted in Pharmacy | Comments Off on PBMI's Annual Drug Benefit Conference Moves to Las Vegas, Nevada — February 18-20, 2013

Pioneer of Canadian Internet pharmacy industry jailed for 4 years in U.S.

Posted: Published on January 10th, 2013

WINNIPEG - A pioneer of the Canadian Internet pharmacy industry has been sentenced to four years in prison by a Miami court. The U.S. Justice Department says Andrew Strempler was sentenced "for his role in a scheme to defraud consumers purchasing pharmaceuticals online." The department also says Strempler was ordered to pay a forfeiture of $300,000 and a fine of $25,000 and that a restitution hearing has been set for Feb. 26. Prosecutors had originally sought up to 20 years in prison and the forfeiture of $95 million in alleged proceeds from his business. Strempler pleaded guilty in October 2012 of conspiracy to commit mail fraud as owner of RxNorth.com, based in Minnedosa, Manitoba. RxNorth.com was an Internet, mail and telephone order pharmacy, through which prescription drugs were sold to American consumers between 2005 and mid-2006. "Internet websites that illegally sell potentially substandard, counterfeit or otherwise unsafe pharmaceuticals, pose a real threat to consumers," said Deputy Assistant Attorney General Stuart Delery. "The sentence handed down today serves as an effective deterrent to those who would peddle counterfeit pharmaceuticals particularly those drugs trafficked over the Internet." The U.S. Justice Department says the Food and Drug Administration wrote to Strempler as early … Continue reading

Posted in Pharmacy | Comments Off on Pioneer of Canadian Internet pharmacy industry jailed for 4 years in U.S.

BrainStorm Establishes Safety of Repeat Doses of NurOwn in Mice; Pre-clinical Study Conducted at GLP-compliant Harlan …

Posted: Published on January 10th, 2013

NEW YORK & PETACH TIKVAH, Israel--(BUSINESS WIRE)-- BrainStorm Cell Therapeutics (BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced that it has successfully completed a 12-week repeat dose toxicity study with its NurOwn cells in mice. The company believes that the positive data from the study will support its efforts to obtain approval for a future repeat dose clinical study in ALS patients. The study was conducted at Harlan Israels laboratories, according to GLP (Good Laboratory Practice) standards of the FDA. The study protocol was approved by the Israeli Ministry of Health. We believe that repeat dosing is the key to the long-term clinical efficacy of NurOwn and we are anxious to begin testing in ALS patients. Our proprietary cryopreservation protocol will enable us to do so without having to perform repeat bone marrow aspirations for each dose, commented Dr. Adrian Harel, BrainStorms CEO. In the study, the animals received up to three intramuscular injections of NurOwn, produced from cryopreserved, or frozen, cells at concentrations 50100 times the currently administered clinical trial dose. The treatment was well tolerated, and no adverse clinical effects were observed. Analyses included cytokine profile assays, clinical pathology, necropsy and macroscopic examination, … Continue reading

Posted in FDA Stem Cell Trials | Comments Off on BrainStorm Establishes Safety of Repeat Doses of NurOwn in Mice; Pre-clinical Study Conducted at GLP-compliant Harlan …

BrainStorm Achieves Important New Development for Commercialization of NurOwn

Posted: Published on January 10th, 2013

NEW YORK & PETACH TIKVAH, Israel--(BUSINESS WIRE)-- BrainStorm Cell Therapeutics (BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has achieved a new breakthrough for commercialization of its stem cell therapy candidate, NurOwn. The company has developed a proprietary method for cryopreservation, or freezing, of cells, which will enable long-term storage, and production of repeat patient doses of NurOwn without the need for additional bone marrow aspirations. Cryopreservation will enable us to create a personalized NurOwn stem cell bank for each patient, for ongoing, repeat treatments, commented Dr. Adrian Harel, BrainStorms CEO. We will be in a position to produce repeat doses of NurOwn by thawing and processing the patients cryopreserved cells, and transporting these doses to medical centers for immediate transplantation. Cryopreservation of hematopoeitic (or blood cell-forming) stem cells for clinical use has been routinely performed for fifteen years. Cryopreservation of mesenchymal stem cells for clinical use is a more recent phenomenon, and is typically done in vapor phase nitrogen. At extreme, sub-zero temperatures, any biological activity, including the biochemical reactions that would cause cell death, is effectively stopped. According to Harel: Our unique method of expansion and differentiation of mesenchymal stem … Continue reading

Posted in Stem Cell Human Trials | Comments Off on BrainStorm Achieves Important New Development for Commercialization of NurOwn

Stem cells may hold promise for Lou Gehrig's disease

Posted: Published on January 10th, 2013

Public release date: 9-Jan-2013 [ | E-mail | Share ] Contact: Rachel Seroka rseroka@aan.com 612-928-6129 American Academy of Neurology SAN DIEGO Apparent stem cell transplant success in mice may hold promise for people with amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease. The results of the study were released today and will be presented at the American Academy of Neurology's 65th Annual Meeting in San Diego, March 16 to 23, 2013. "There have been remarkable strides in stem cell transplantation when it comes to other diseases, such as cancer and heart failure," said study author Stefania Corti, MD, PhD, with the University of Milan in Italy and a member of the American Academy of Neurology. "ALS is a fatal, progressive, degenerative disease that currently has no cure. Stem cell transplants may represent a promising avenue for effective cell-based treatment for ALS and other neurodegenerative diseases." For the study, mice with an animal model of ALS were injected with human neural stem cells taken from human induced pluripotent stem cells (iPSCs). iPSC are adult cells such as skin cells that have been genetically reprogrammed to an embryonic stem cell-like state. Neurons are a basic building block of the nervous system, which … Continue reading

Posted in Stem Cell Human Trials | Comments Off on Stem cells may hold promise for Lou Gehrig's disease

Stem cells may hold promise for Lou Gehrig’s disease (ALS)

Posted: Published on January 10th, 2013

Jan. 9, 2013 Apparent stem cell transplant success in mice may hold promise for people with amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease. The results of the study were released today and will be presented at the American Academy of Neurology's 65th Annual Meeting in San Diego, March 16 to 23, 2013. "There have been remarkable strides in stem cell transplantation when it comes to other diseases, such as cancer and heart failure," said study author Stefania Corti, MD, PhD, with the University of Milan in Italy and a member of the American Academy of Neurology. "ALS is a fatal, progressive, degenerative disease that currently has no cure. Stem cell transplants may represent a promising avenue for effective cell-based treatment for ALS and other neurodegenerative diseases." For the study, mice with an animal model of ALS were injected with human neural stem cells taken from human induced pluripotent stem cells (iPSCs). iPSC are adult cells such as skin cells that have been genetically reprogrammed to an embryonic stem cell-like state. Neurons are a basic building block of the nervous system, which is affected by ALS. After injection, the stem cells migrated to the spinal cord of the mice, matured … Continue reading

Posted in Stem Cell Human Trials | Comments Off on Stem cells may hold promise for Lou Gehrig’s disease (ALS)

BioTime Submits Protocol for Initiation of Human Clinical Trials of Renevia™ in Europe

Posted: Published on January 10th, 2013

ALAMEDA, Calif.--(BUSINESS WIRE)-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced it has submitted a Clinical Investigation Protocol (CIP) to European regulatory authorities for approval to initiate studies for its Renevia stem cell delivery platform. The Principal Investigator for the studies will be Ramon Llull, MD, and the planned trials will be conducted at the Stem Center, Palma de Mallorca, Spain (www.stem-center.com). The Stem Center is operated by the GID Group, Inc., of Louisville, Colorado. BioTime is currently completing the production of clinical materials according to current Good Manufacturing Practice regulations. The initiation of human clinical studies is expected in Q2 of this year upon approval of the CIP. Renevia, a member of the Companys HyStem family of hydrogels, is a proprietary formulation that mimics the human extracellular matrix, a web of molecules surrounding cells that is essential to cellular function. Renevia is designed to be a liquid injectable matrix capable of safely polymerizing in the body into a three-dimensional tissue-like scaffold in combination with transplanted cells. Anchoring the transplanted cells in such a biocompatible matrix generally increases the percentage of viable cell engraftment. HyStem hydrogels are … Continue reading

Comments Off on BioTime Submits Protocol for Initiation of Human Clinical Trials of Renevia™ in Europe

Doctors Warn Against Fatal Stem Cell Complications

Posted: Published on January 10th, 2013

MANILA Philippines --- Doctors yesterday warned against the fatal complications of the use of stem cell therapy. According to the Philippine Society for Stem Cell Medicine (PSSCM), a stem cell transplant poses a host of complications, including fatal complications that depend on several factors such as the type of blood disorder, type of transplant, and the age and health of the person receiving the transplant. "If the stem cell that you received is not from your own body, it could lead to fatal complications," PSSCM said. The Philippine Medical Association (PMA) also warned that a patient's body may reject the transplant stem cells from a donor. "Although some people experience few problems with a transplant, others may develop complications that may require treatment or hospitalization. Some complications could even be life-threatening," Dr. Leo Olarte, PMA vice president said. According to Olarte, the complications that can arise from a stem cell transplant include graft-versus-host disease, stem cell (graft) failure, organ injury, infections, cataracts, infertility, new cancers, and even death. According to Olarte, a person who will undergo a stem cell transplant from a donor (allogeneic stem cell transplant) may be at risk of graft-versus-host disease. "This condition occurs when a donor's … Continue reading

Comments Off on Doctors Warn Against Fatal Stem Cell Complications

Page 5,880«..1020..5,8795,8805,8815,882..5,8905,900..»